VK2735
GIP/GLP-1 · s.c. / oral · Viking Therapeutics
Summary
- Also known as
- Viking Therapeutics
- Mechanism
- GIP/GLP-1
- Route
- s.c. / oral
- Company
- Viking Therapeutics
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 3: s.c. VANQUISH-1/-2 (since 2025); oral SUNRISE-1/-2 started Oct 2026 (obesity with and without T2D); VENTURE s.c. phase 2 published (Obesity 2026) verify
- Next milestone
- VANQUISH readouts; SUNRISE enrolment
Sources for the status
- Viking Therapeutics, Inc.. A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition (VANQUISH 1). ClinicalTrials.gov identifier NCT07104500. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07104500
- Viking Therapeutics. Initiation of the VK2735 oral phase 3 programme (SUNRISE) [press release]. 2026 Oct 14. Available from: https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity
Indications: regulatory and evidence status
| Indication | Code | Status | Evidence |
|---|---|---|---|
| Obesity | 2 phase 3 ongoing | VANQUISH phase 3 ongoing | VANQUISH 1 |
| T2D | 2 phase 3 ongoing | VANQUISH 2 ongoing | VANQUISH 2 |
| CV outcomes | 0 no data | ||
| CKD | 0 no data | ||
| HFpEF | 0 no data | ||
| MASH | 0 no data | ||
| Sleep apnoea | 0 no data | ||
| Knee OA | 0 no data | ||
| Alzheimer's | 0 no data |
4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VENTURE (phase 2, s.c.) | VK2735 5.0 mg weekly | obesity | 13 | 35 | −10.9 % vs −1.7 % Δ −9.2 pp | — | −0.3 vs +0.0 | 11.0 vs 0.0 | 11.0 vs 14.0 | 46.0 vs 20.0 | 17.0 vs 0.0 | 6.0 vs 3.0 | −6.7 vs −4.2 | verified |
| VENTURE (phase 2, s.c.) | VK2735 10 mg weekly | obesity | 13 | 36 | −12.9 % vs −1.7 % Δ −11.2 pp | — | −0.3 vs +0.0 | 11.0 vs 0.0 | 14.0 vs 14.0 | 37.0 vs 20.0 | 17.0 vs 0.0 | 6.0 vs 3.0 | −7.0 vs −4.2 | verified |
| VENTURE (phase 2, s.c.) | VK2735 15 mg weekly | obesity | 13 | 35 | −14.7 % vs −1.7 % Δ −13.0 pp | — | −0.4 vs +0.0 | 20.0 vs 0.0 | 20.0 vs 14.0 | 63.0 vs 20.0 | 29.0 vs 0.0 | 3.0 vs 3.0 | −11.0 vs −4.2 | verified |
| VENTURE-Oral (phase 2) | oral VK2735 90 mg daily | obesity | 13 | 40 | — | —−11.1 % vs −1.3 % estimand not specified | — | — | 25.0 vs 18.0 | — | — | — | — | verified |
| VENTURE-Oral (phase 2) | oral VK2735 120 mg daily | obesity | 13 | 40 | — | —−12.2 % vs −1.3 % estimand not specified | — | — | 38.0 vs 18.0 | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- oral VK2735 90 mg daily: Press release: estimand not stated Nausea and vomiting are reported only as drug-related events by severity (not shown on the axis).
- oral VK2735 120 mg daily: Press release: estimand not stated Nausea and vomiting are reported only as drug-related events by severity (not shown on the axis).
Verbatim quotes from the source (28)
- VK2735 5.0 mg weekly · weight_eff · Table 2
LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
- VK2735 5.0 mg weekly · ae_dc · Table 3
TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
- VK2735 5.0 mg weekly · disc_any · Table 3
Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
- VK2735 5.0 mg weekly · nausea · Table 3
Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
- VK2735 5.0 mg weekly · vomiting · Table 3
Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
- VK2735 5.0 mg weekly · sae · Table 3
TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
- VK2735 5.0 mg weekly · hba1c · Table 5, Hemoglobin A1c
Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
- VK2735 5.0 mg weekly · sbp · Table 5, Systolic blood pressure
Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
- VK2735 10 mg weekly · weight_eff · Table 2
LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
- VK2735 10 mg weekly · ae_dc · Table 3
TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
- VK2735 10 mg weekly · disc_any · Table 3
Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
- VK2735 10 mg weekly · nausea · Table 3
Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
- VK2735 10 mg weekly · vomiting · Table 3
Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
- VK2735 10 mg weekly · sae · Table 3
TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
- VK2735 10 mg weekly · hba1c · Table 5, Hemoglobin A1c
Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
- VK2735 10 mg weekly · sbp · Table 5, Systolic blood pressure
Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
- VK2735 15 mg weekly · weight_eff · Table 2
LS Mean (95% CI) −1.7 (−3.03, −0.30) −9.1 (−10.43, −7.76) −10.9 (−12.25, −9.55) −12.9 (−14.30, −11.56) −14.7 (−16.11, −13.38)
- VK2735 15 mg weekly · ae_dc · Table 3
TEAE leading to treatment discontinuation 0 1 (3) 4 (11) 4 (11) 7 (20)
- VK2735 15 mg weekly · disc_any · Table 3
Discontinued treatment early, n (%)c 5 (14) 2 (6) 4 (11) 5 (14) 7 (20)
- VK2735 15 mg weekly · nausea · Table 3
Nausea 7 (20) 9 (26) 16 (46) 13 (37) 22 (63)
- VK2735 15 mg weekly · vomiting · Table 3
Vomiting 0 3 (9) 6 (17) 6 (17) 10 (29)
- VK2735 15 mg weekly · sae · Table 3
TESAEs, n (%)a 1 (3) 2 (6) 2 (6) 2 (6) 1 (3)
- VK2735 15 mg weekly · hba1c · Table 5, Hemoglobin A1c
Change from BL, LS Mean (SE) 0.03 (0.041) −0.29 (0.040) −0.27 (0.040) −0.27 (0.039) −0.36 (0.040)
- VK2735 15 mg weekly · sbp · Table 5, Systolic blood pressure
Change from BL, LS Mean (SE) −4.20 (1.993) −6.87 (1.906) −6.71 (1.931) −7.04 (1.936) −10.97 (2.000)
- oral VK2735 90 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
- oral VK2735 90 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %
- oral VK2735 120 mg daily · disc_any · Discontinuation Rates and Common GI TEAEs table
Discontinued treatment early 7 (18 %) 8 (20 %) 8 (20 %) 11 (28 %) 10 (25 %) 15 (38 %)
- oral VK2735 120 mg daily · weight_unsp · Table: Observed Change in Body Weight Following 13 Weeks
Mean percent change from baseline 4,5 -1.3 % -2.3 % -7.0 % -8.7 % -11.1 % -12.2 %
Registered trials (4)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| SUNRISE 1 Oral VK2735 for Weight Management Phase 3 (SUNRISE 1) | Obesity | Phase 3 | not yet recruiting | 2026-11 → 2028-07 | 560 | not yet recruiting | NCT07868835 |
| SUNRISE 2 Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2) | Obesity | Phase 3 | not yet recruiting | 2026-11 → 2028-10 | 560 | not yet recruiting | NCT07868939 |
| VANQUISH 2 VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Obesity | Phase 3 | active not recruiting | 2025-06 → 2027-07 | 1100 | active not recruiting | NCT07104383 |
| VANQUISH 1 VK2735 for Weight Management Phase 3 | Obesity | Phase 3 | active not recruiting | 2025-06 → 2027-07 | 4500 | active not recruiting | NCT07104500 |
Primary sources
- Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J, et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026;34(3):537-549. PMID: 41508550.
- Viking Therapeutics. Viking Therapeutics announces positive top-line results from phase 2 VENTURE-Oral Dosing trial of VK2735 tablet formulation in patients with obesity [press release]. San Diego (CA): Viking Therapeutics; 2025 Aug 19. Available from: https://ir.vikingtherapeutics.com/2025-08-19-Viking-Therapeutics-Announces-Positive-Top-Line-Results-from-Phase-2-VENTURE-Oral-Dosing-Trial-of-VK2735-Tablet-Formulation-in-Patients-With-Obesity
How to cite this page
Cite the primary publication for any single result; every value above links to it.